Dasiglucagon: First Approval

Drugs. 2021 Jun;81(9):1115-1120. doi: 10.1007/s40265-021-01531-z.


Dasiglucagon (Zegalogue®) is an antihypoglycaemic agent being developed by Zealand Pharma for the treatment of hypoglycaemia, type 1 diabetes mellitus (T1DM) management and congenital hyperinsulinism. In March 2021, dasiglucagon received its first approval in the USA for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes aged 6 years and above. Dasiglucagon, a glucagon analogue, is available as a single-dose autoinjector or prefilled syringe for subcutaneous injection. This article summarizes the milestones in the development of dasiglucagon leading to this first approval for hypoglycaemia.

Publication types

  • Review

MeSH terms

  • Blood Glucose
  • Clinical Trials, Phase III as Topic
  • Diabetes Mellitus, Type 1 / complications*
  • Double-Blind Method
  • Glucagon / administration & dosage
  • Glucagon / adverse effects
  • Glucagon / analogs & derivatives*
  • Glucagon / pharmacology
  • Glucagon / therapeutic use
  • Humans
  • Hyperinsulinism / drug therapy
  • Hypoglycemia / drug therapy*
  • Hypoglycemia / etiology*
  • Injections, Subcutaneous
  • Randomized Controlled Trials as Topic


  • Blood Glucose
  • dasiglucagon
  • Glucagon